Moderna: token EPS in Q3

(CercleFinance.com) - Moderna reports Q3 2024 EPS of $0.
03, compared with a loss of $9.53 per share a year earlier, with total sales of $1.9bn, compared with $1.8bn in Q3 2023. NB: pmt +9.7%.

Its net product sales rose by 4% to $1.8bn, growth mainly attributable to the US market following the launch of the updated Covid-19 vaccine, while its international sales declined.

For 2024, Moderna reiterates its forecast of net product sales of $3bn to $3.5bn from its respiratory franchise, but now expects only cost of sales of between 40% and 45% of product sales, with R&D expenditure of $4.6bn to $4.7bn.

Management remains focused on supporting sales growth, obtaining 10 product approvals over the next three years, and continuing to reduce our cost structure.


Copyright (c) 2024 CercleFinance.com. All rights reserved.